Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 16, 2009

Talecris Pours $268.7M into Production Plant in North Carolina

  • Talecris Biotherapeutics is expanding its manufacturing facilities in Clayton, NC, and expects to spend $268.7 million. The Clayton plant produces protein therapies that are used to treat a range of diseases including immune deficiencies, hemophilia, genetic emphysema, and chronic inflammatory demyelinating polyneuropathy.

    To facilitate Talecris’ manufacturing expansion, the state has awarded the company a $250,000 grant from the One North Carolina Fund. In addition, the state Economic Investment Committee today voted to award a job-development investment grant to Talecris.

    Talecris currently employs approximately 4,700 people worldwide and is headquartered in Research Triangle Park, NC. The expansion will add another 259 jobs. Talecris has 11 approved products on the market, each of them derived from human plasma that is collected primarily from the company’s 71 plasma donation centers nationwide.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »